Article
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome
2022-04-02
Abstract excerpt
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover characteristics that predict pembrolizumab response. Samples were analyzed before and after 3 weeks of pembrolizumab treatment by single-cell RNA-sequencing of 118,9...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 72ed597c-620d-5d11-95ed-6fbfcb672bcf
- DOI
- 10.1101/2022.03.29.22272994
